Effect of CYP3A4*18B, CYP3A5*3 gene polymorphism on dosage and concentration of tacrolimus in renal transplant patients.
- Author:
Lin ZHU
1
;
Hong-Tao SONG
;
Qing-Hua WANG
;
Wei-Zhen WU
;
Shun-Liang YANG
;
Jian-Ming TAN
Author Information
1. Department of Pharmacy, Fuzhou General Hospital of Nanjing Military Region, Fuzhou 350025, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Alleles;
Cytochrome P-450 CYP3A;
genetics;
Digestive System Diseases;
chemically induced;
Dose-Response Relationship, Drug;
Female;
Genotype;
Graft Rejection;
genetics;
Humans;
Immunosuppressive Agents;
administration & dosage;
adverse effects;
blood;
therapeutic use;
Kidney Transplantation;
Male;
Middle Aged;
Polymorphism, Genetic;
Retrospective Studies;
Tacrolimus;
administration & dosage;
adverse effects;
blood;
therapeutic use
- From:
Acta Pharmaceutica Sinica
2012;47(7):878-883
- CountryChina
- Language:Chinese
-
Abstract:
The effect of CYP3A4*18B and CYP3A5*3 on concentration/dosage x body surface area ratios (C/D'), adverse effects and acute rejection of tacrolimus in renal transplant patients were investigated. The CYP3A4*18B genotypes of 227 renal transplant patients were determined by PCR-RFLP method. The differences of C/D' ratios, adverse reactions and acute rejection were compared among all of the genotype groups treated with tacrolimus. The frequencies of CYP3A4*18 and CYP3A5*3 alleles in renal transplant patients were 30.8% and 74.2%, respectively. No significant association was found between the C/D's of tacrolimus and CYP3A4*18B genotypes when they were classified by two CYP3A5 genotypes (P > 0.05). While after the effects of CYP3A4*18B genotype were eliminated, the C/D' ratio of tacrolimus in patients with CYP3A5*1/*1 and *1/*3 genotype group was significantly lower than those with CYP3A5*3/*3 genotype groups (P < 0.01). There is no significant difference in adverse effects and acute rejection among different genotypes (P > 0.05).
